Pipeline

OVERVIEW

Our current pipeline consists of new molecular entities with relevant mechanism of actions in skin diseases, targeting significant market opportunities in the global dermatology market.

PIPELINE

PRODUCT
CANDIDATE
MOA &
INDICATION
PRE-
CLINICAL
PHASE
1
PHASE
2a
PHASE
2b
PHASE
3
Topical soft anticholinergic for axillary hyperhidrosis

Title

44%
Oral rexinoid for cutaneous T-cell lymphoma

Title

22%
Topical RORγ inhibitor for psoriasis

Title

7%
Targeting various skin diseases

Title

7%